Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years
在中国开展的贝利木单抗治疗系统性红斑狼疮患者的III期长期开放标签扩展研究,旨在评估其安全性和有效性,研究周期长达6年。
期刊:RMD Open
影响因子:4.7
doi:10.1136/rmdopen-2021-001669
Zhang, Fengchun; Zheng, Jie; Li, Yang; Wang, Guochun; Wang, Mingjun; Su, Yin; Gu, Jieruo; Li, Xingfu; Bass, Damon; Chu, Myron; Curtis, Paula; DeRose, Kathleen; Kurrasch, Regina; Lowe, Jenny; Meizlik, Paige; Roth, David A